Oxbryta (Voxelotor) Leads
Connect with sickle cell disease patients and their families who suffered serious adverse events, including vaso-occlusive crisis, stroke, or death, from the recalled drug Oxbryta (voxelotor).
Oxbryta Sickle Cell Drug Litigation
Oxbryta (voxelotor), manufactured by Pfizer (formerly Global Blood Therapeutics), was approved to treat sickle cell disease in patients aged four and older. The FDA requested Pfizer voluntarily withdraw the drug from the market after post-marketing data revealed an imbalance of deaths and vaso-occlusive crises in patients taking Oxbryta compared to placebo. Lawsuits allege the manufacturer downplayed safety signals and continued marketing the drug despite evidence of serious harm.
Associated Conditions
- Vaso-occlusive crisis
- Death
- Stroke
- Acute chest syndrome
- Organ damage
- Worsening sickle cell complications
- Hospitalization for adverse drug events
Claimant Eligibility
- Prescribed and took Oxbryta (voxelotor) for sickle cell disease
- Experienced vaso-occlusive crisis, stroke, or other serious adverse event
- Hospitalized or required emergency treatment while on Oxbryta
- Family member of a patient who died while taking Oxbryta
- Medical records confirming Oxbryta prescription and adverse events
Why Law Firms Choose Us
Exclusive Leads
Every lead is yours alone. We never resell or share claimant information with competing firms, guaranteeing you first-mover advantage on every case.
Pre-Qualified Claimants
Our intake specialists screen every potential claimant against your specific case criteria before delivery, so your team only speaks with viable cases.
Live Transfer
Qualified claimants are transferred directly to your intake team in real time, maximizing conversion rates and reducing time-to-retainer.